Antimicrobial Agents Practice Questions

Q: Which of the following antiretroviral drugs is a non-nucleoside reverse transcriptase inhibitor?

Efavirenz. ### Explanation **Correct Answer: B. Efavirenz** **Mechanism and Classification:** Antiretroviral therapy (ART) is classified based on the stage of the HIV life cycle the drugs inhibit [2]. **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)** like **Efavirenz** bind directly and non-competitively to the enzyme reverse transcriptase at a site distinct from the active site (allosteric site). This induces a conformational change that inhibits the conversion of viral RNA to DNA. Unlike NRTIs, NNRTIs do not require intracellular phosphorylation to become active. **Analysis of Incorrect Options:** * **A. Zidovudine (AZT) & D. Stavudine (d4T):** These are **Nucleoside Reverse Transcriptase Inhibitors (NRTIs)** [3]. They act as competitive inhibitors and "chain terminators" [1]. They are structural analogs of native nucleosides and must be phosphorylated by host cell kinases into triphosphate forms to be active [1]. * **C. Saquinavir:** This is a **Protease Inhibitor (PI)** [3]. It inhibits the viral protease enzyme, preventing the cleavage of precursor polyproteins (gag-pol), which results in the production of immature, non-infectious virions [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Efavirenz Side Effects:** Characteristically causes **CNS side effects** (vivid dreams, nightmares, dizziness, and "hangover" feeling). It is also associated with **teratogenicity** (neural tube defects), though recent guidelines have relaxed restrictions in pregnancy. * **Nevirapine (another NNRTI):** Known for causing severe hepatotoxicity and Stevens-Johnson Syndrome (SJS) [4]. It was historically used to prevent mother-to-child transmission (MTCT). * **Mnemonic for NNRTIs:** "**DEN**" – **D**elavirdine, **E**favirenz, **N**evirapine (and newer agents like Etravirine and Rilpivirine). * **Zidovudine** is specifically known for causing **bone marrow suppression** (anemia/neutropenia).

Q: Which of the following can be given as a single dose antimalarial for P.vivax malaria?

Pyrimethamine + Sulfadoxime. **Explanation:** The combination of **Pyrimethamine and Sulfadoxime (S/P)** is characterized by an exceptionally long half-life (Sulfadoxime ~7–9 days; Pyrimethamine ~4 days). This pharmacological profile allows for **single-dose administration**, ensuring high patient compliance. It acts via sequential blockade of folic acid synthesis, targeting the erythrocytic schizonts of malaria parasites. While primarily used for *P. falciparum*, it is also effective against the erythrocytic stages of *P. vivax*. **Analysis of Incorrect Options:** * **A. Atovaquone + Proguanil:** This combination (Malarone) requires a **3-day course** for treatment or daily administration for prophylaxis. It is not used as a single dose. * **B. Artemisinin:** Artemisinin derivatives (like Artesunate or Artemether) have very short half-lives. When used as monotherapy, they require at least 5–7 days of treatment; in ACT (Artemisinin-based Combination Therapy), they are typically given for **3 days**. * **C. Quinine + Tetracycline:** Quinine has a short half-life and narrow therapeutic index, requiring dosing every 8 hours for **7 days**. Tetracycline also requires a 7-day course. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** S/P inhibits Dihydrofolate Reductase (Pyrimethamine) and Dihydropteroate Synthase (Sulfadoxime). * **Radical Cure:** Note that while S/P treats the blood stage of *P. vivax*, a **14-day course of Primaquine** (or a single dose of **Tafenoquine**) is mandatory to clear the **hypnozoites** (liver stage) and prevent relapse. * **Contraindication:** Avoid S/P in patients with sulfa allergies or severe renal/hepatic failure. It is also avoided in the first trimester of pregnancy due to antifolate effects.

Q: Among the drugs listed, which is LEAST likely to be implicated in drug-induced hepatitis?

Streptomycin. **Explanation:** The core concept in this question is the distinction between **Hepatotoxic** and **Non-hepatotoxic** Anti-Tubercular Drugs (ATD). **Why Streptomycin is the correct answer:** Streptomycin is an **Aminoglycoside**. Unlike the first-line oral agents, it is primarily excreted unchanged by the kidneys via glomerular filtration. It does not undergo significant hepatic metabolism and, therefore, lacks the potential for drug-induced liver injury (DILI). Its primary toxicities are **ototoxicity** (vestibulocochlear nerve damage) and **nephrotoxicity**. **Analysis of Incorrect Options:** * **Pyrazinamide (D):** This is the **most hepatotoxic** drug among the first-line ATD regimen. It causes dose-dependent hepatotoxicity and can lead to severe liver necrosis. * **Isoniazid (A):** It is a major cause of drug-induced hepatitis. Toxicity is mediated by its metabolite, **acetylhydrazine**. The risk is higher in "slow acetylators" and older patients. * **Rifampicin (C):** While less hepatotoxic than Pyrazinamide or Isoniazid, it is a potent **enzyme inducer**. It can cause transient asymptomatic jaundice and often potentiates the hepatotoxicity of Isoniazid by increasing the formation of toxic metabolites. **NEET-PG High-Yield Pearls:** 1. **Hepatotoxicity Order:** Pyrazinamide > Isoniazid > Rifampicin. 2. **Safe in Liver Disease:** If a patient develops jaundice during ATT, the hepatotoxic drugs (H, R, Z) are stopped. The safest alternatives are **Streptomycin** and **Ethambutol**. 3. **Visual Side Effects:** Remember that Ethambutol is associated with optic neuritis (red-green color blindness), not hepatitis. 4. **Monitoring:** If ALT/AST levels rise to >3 times the upper limit of normal with symptoms, or >5 times without symptoms, hepatotoxic drugs must be discontinued.

Q: Which of the following is NOT included in the treatment of Mycobacterium avium complex?

Pyrazinamide. **Explanation:** The **Mycobacterium avium complex (MAC)** consists of *M. avium* and *M. intracellulare*. Unlike *Mycobacterium tuberculosis*, MAC is **intrinsically resistant** to most standard first-line antitubercular drugs, most notably **Pyrazinamide**. 1. **Why Pyrazinamide (D) is the correct answer:** Pyrazinamide requires an acidic environment and the enzyme pyrazinamidase to be converted into its active form (pyrazinoic acid). MAC lacks the specific susceptibility mechanisms required for Pyrazinamide to be effective; therefore, it has no role in the treatment of MAC infections. 2. **Why the other options are incorrect:** * **Clarithromycin (B):** Macrolides (Clarithromycin or Azithromycin) are the **cornerstone** of MAC therapy. They inhibit protein synthesis and are essential for both prophylaxis and treatment. * **Rifabutin (C):** This is a rifamycin preferred over Rifampin for MAC because it is more potent against this complex and has fewer drug-drug interactions in HIV patients on HAART. * **Ciprofloxacin (A):** Fluoroquinolones (like Ciprofloxacin or Moxifloxacin) are considered **second-line or adjunctive agents** used in multidrug regimens for macrolide-resistant MAC or disseminated disease. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Regimen for MAC:** Clarithromycin + Ethambutol + Rifabutin. * **Prophylaxis:** In HIV patients with **CD4 counts <50 cells/mm³**, primary prophylaxis with Azithromycin or Clarithromycin is indicated. * **Key Distinction:** Pyrazinamide is only used for *M. tuberculosis*; it is ineffective against almost all Non-Tuberculous Mycobacteria (NTM).

Q: Which of the following antibiotics is not used in the treatment of enterococcal infections?

Cephalexin. **Explanation:** The correct answer is **Cephalexin (Option D)**. The fundamental pharmacological concept to remember for NEET-PG is that **Enterococci are inherently resistant to all Cephalosporins.** This is due to the low affinity of enterococcal Penicillin-Binding Proteins (PBPs), specifically PBP5, for cephalosporins. Therefore, regardless of the generation, cephalosporins (like Cephalexin, a 1st generation agent) are never used to treat enterococcal infections. **Analysis of Options:** * **Vancomycin (Option A):** A glycopeptide that is traditionally the drug of choice for serious ampicillin-resistant enterococcal infections. It inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus. * **Linezolid (Option B):** An oxazolidinone used primarily for Vancomycin-Resistant Enterococci (VRE). It inhibits protein synthesis by binding to the 50S ribosomal subunit. * **Teicoplanin (Option C):** Another glycopeptide similar to Vancomycin. It is effective against many strains of *Enterococcus faecalis* and *E. faecium*, though some VRE strains (VanA phenotype) are also resistant to it. **High-Yield Clinical Pearls for NEET-PG:** 1. **LAME mnemonic:** Cephalosporins lack activity against **L**isteria, **A**typicals (Mycoplasma/Chlamydia), **M**RSA (except Ceftaroline), and **E**nterococci. 2. **Synergy:** For serious enterococcal infections (e.g., endocarditis), an aminoglycoside (Gentamicin) is added to a cell-wall active agent (Ampicillin or Vancomycin) for bactericidal synergy. 3. **Drug of Choice:** For uncomplicated *E. faecalis*, **Ampicillin** remains the first-line treatment. For VRE, **Linezolid** or **Daptomycin** are preferred.

Q: A 29-year-old female diagnosed with AIDS presents with progressive blurring of vision in her right eye. Fundoscopic examination reveals a small, white, opaque lesion on the retina. What is the most appropriate therapy for this patient?

Ganciclovir. The clinical presentation of progressive blurring of vision and a white, opaque retinal lesion in a patient with AIDS is highly suggestive of **CMV Retinitis**. This is the most common opportunistic ocular infection in HIV-infected individuals, typically occurring when the CD4 count falls below 50 cells/mm³ [1, 2]. **1. Why Ganciclovir is Correct:** Ganciclovir is the first-line treatment for CMV infections [1, 2]. It is a guanosine analogue that requires initial phosphorylation by a viral protein kinase (**UL97**) to ganciclovir monophosphate, followed by conversion to the triphosphate form by host cell kinases. This active form competitively inhibits viral DNA polymerase, terminating CMV DNA synthesis. **2. Why Other Options are Incorrect:** * **Acyclovir:** Primarily used for HSV and VZV. It is ineffective against CMV because CMV lacks the viral thymidine kinase required to activate acyclovir. * **Amantadine:** An antiviral agent used for Influenza A (by inhibiting the M2 ion channel) and Parkinson’s disease. It has no activity against DNA viruses like CMV. * **Flucytosine:** An antifungal agent used in combination with Amphotericin B for Cryptococcal meningitis. It has no antiviral properties. **High-Yield Clinical Pearls for NEET-PG:** * **CMV Retinitis Appearance:** Often described as "pizza-pie" or "cottage cheese and ketchup" appearance (hemorrhage with exudates). * **Side Effects:** The dose-limiting toxicity of Ganciclovir is **bone marrow suppression** (neutropenia, thrombocytopenia). * **Alternative Drugs:** If Ganciclovir resistance occurs (UL97 mutation), **Foscarnet** or **Cidofovir** are used; these do not require viral phosphorylation for activation [3]. * **Valganciclovir:** The oral prodrug of ganciclovir, often used for maintenance therapy [3].

Q: Which of the following is NOT a NNRTI?

Ritonavir. The correct answer is **Ritonavir** because it belongs to the **Protease Inhibitor (PI)** class of antiretroviral therapy (ART), not the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) class. ### **Explanation of Options** * **Ritonavir (Option A):** This is a Protease Inhibitor. In modern clinical practice, it is primarily used as a **"pharmacokinetic enhancer" (booster)**. It inhibits the CYP3A4 enzyme, thereby increasing the plasma concentrations and half-life of other protease inhibitors (like Lopinavir or Atazanavir). * **Nevirapine (Option B):** A first-generation NNRTI. It is well-known for its role in preventing mother-to-child transmission of HIV, though it is associated with a high risk of hepatotoxicity and severe skin rashes (Stevens-Johnson Syndrome). * **Efavirenz (Option C):** A first-generation NNRTI. It is a high-yield topic due to its unique side effect profile, including **neuropsychiatric symptoms** (vivid dreams, insomnia, psychosis) and potential teratogenicity (neural tube defects). * **Delavirdine (Option D):** A first-generation NNRTI. It is less commonly used in clinical practice today but remains a classic textbook example of the NNRTI class. ### **High-Yield Clinical Pearls for NEET-PG** 1. **Mechanism of Action:** NNRTIs bind to a **hydrophobic pocket** (allosteric site) on the HIV-1 Reverse Transcriptase enzyme, causing a conformational change. Unlike NRTIs, they do *not* require phosphorylation to become active and do *not* compete with nucleosides. 2. **Class Specificity:** NNRTIs are active only against **HIV-1**, whereas NRTIs and PIs are active against both HIV-1 and HIV-2. 3. **Second Generation NNRTIs:** Remember **Etravirine** and **Rilpivirine**; these are often used when resistance develops to first-generation agents. 4. **Mnemonic for NNRTIs:** "The **NED** family" (**N**evirapine, **E**favirenz, **D**elavirdine).

Q: What is the drug of choice for the treatment of chlamydial infection?

Doxycycline. **Explanation:** **Chlamydia trachomatis** is an obligate intracellular bacterium, meaning it lacks a traditional peptidoglycan cell wall and resides within host cells. Therefore, the drug of choice must have excellent intracellular penetration and the ability to inhibit bacterial protein synthesis. * **Why Doxycycline is correct:** Doxycycline (a tetracycline) is the **Drug of Choice (DOC)** for uncomplicated genital chlamydial infections. It acts by binding to the 30S ribosomal subunit, inhibiting protein synthesis. According to the latest CDC guidelines, a 7-day course of Doxycycline is preferred over a single dose of Azithromycin due to higher efficacy in eradicating rectal and urethral infections. * **Why other options are incorrect:** * **Ampicillin & 3rd Gen Cephalosporins:** These are Beta-lactams that act by inhibiting cell wall synthesis. Since *Chlamydia* lacks a classic cell wall, these agents are largely ineffective. * **Metronidazole:** This is an antiprotozoal and anaerobic antibacterial agent. It is the DOC for *Trichomonas vaginalis*, Bacterial Vaginosis, and *Entamoeba histolytica*, but has no activity against *Chlamydia*. **High-Yield Clinical Pearls for NEET-PG:** * **Pregnancy:** Doxycycline is contraindicated in pregnancy (causes fetal teeth discoloration). The DOC for Chlamydia in pregnant women is **Azithromycin** (1g orally, single dose). * **Lymphogranuloma Venereum (LGV):** Caused by *C. trachomatis* (L1-L3 serovars), the treatment is Doxycycline for 21 days. * **Syndromic Management:** In the WHO/NACO syndromic approach, Chlamydia is often co-treated with Gonorrhea using a combination of **Ceftriaxone (IM)** and **Azithromycin/Doxycycline (Oral)**.

Q: Clavulanic acid is given in combination with amoxicillin in order to:

Extend amoxicillin's antibacterial spectrum. **Explanation:** The correct answer is **D. Extend amoxicillin's antibacterial spectrum.** **Mechanism of Action:** Amoxicillin is a beta-lactam antibiotic that is susceptible to degradation by **beta-lactamase enzymes** produced by certain bacteria (e.g., *Staphylococcus aureus*, *H. influenzae*, and *E. coli*). Clavulanic acid is a **"suicide inhibitor"** of beta-lactamase. It has negligible antibacterial activity of its own but binds irreversibly to the beta-lactamase enzyme, protecting amoxicillin from destruction. This allows amoxicillin to inhibit bacterial cell wall synthesis in organisms that would otherwise be resistant, thereby effectively **extending its spectrum** to include beta-lactamase-producing strains. **Analysis of Incorrect Options:** * **A. Reduce allergic reactions:** Clavulanic acid does not modulate the immune system; hypersensitivity reactions (Type I-IV) are inherent to the penicillin structure itself. * **B. Prolong half-life:** The half-life of amoxicillin is determined by renal excretion. Clavulanic acid does not interfere with the renal tubular secretion of amoxicillin (unlike Probenecid, which does). * **C. Reduce diarrhea:** In fact, the combination (Co-amoxiclav) is **more likely** to cause diarrhea and GI upset than amoxicillin alone, as clavulanic acid increases gut motility. **High-Yield NEET-PG Pearls:** * **Other Beta-lactamase Inhibitors:** Sulbactam (paired with Ampicillin) and Tazobactam (paired with Piperacillin). * **Suicide Inhibition:** Clavulanic acid is the classic example where the inhibitor is chemically modified by the enzyme during the process of inhibition. * **Clinical Note:** Co-amoxiclav is a notorious cause of **drug-induced cholestatic jaundice**, a side effect specifically attributed to the clavulanate component.

Q: In cotrimoxazole, what is the ratio of sulphamethoxazole to trimethoprim?

5:1. The original explanation provided the answer details without citations. **Cotrimoxazole** is a fixed-dose combination of **Sulphamethoxazole (SMZ)** and **Trimethoprim (TMP)**. [1] The correct ratio in the formulation is **5:1** (e.g., 400 mg SMZ + 80 mg TMP). [3] **1. Why 5:1 is the Correct Answer:** While both drugs act on the same metabolic pathway (folic acid synthesis), they have different pharmacokinetic profiles. [1] Trimethoprim is significantly more lipid-soluble and has a larger volume of distribution than Sulphamethoxazole. To achieve the **optimal synergistic plasma concentration ratio of 20:1** (which is required for maximum bactericidal effect), the drugs must be administered in a **5:1 dose ratio**. [3] This compensates for the difference in their distribution and clearance rates. [4] **2. Analysis of Incorrect Options:** * **A (2:1) & B (1:1):** These ratios would result in insufficient plasma levels of Trimethoprim relative to Sulphamethoxazole, failing to reach the 20:1 steady-state plasma concentration needed for synergy. * **D (4:5):** This is mathematically incorrect and does not align with any standard pharmacological preparation of these agents. [3] **3. NEET-PG High-Yield Clinical Pearls:** * **Mechanism of Action:** Sequential blockade of folate synthesis. [2] SMZ inhibits *Dihydropteroate synthase*, while TMP inhibits *Dihydrofolate reductase*. [1] * **Nature of Action:** Individually, both drugs are bacteriostatic; in combination (Cotrimoxazole), they become **bactericidal**. [2][3] * **Drug of Choice (DOC):** Cotrimoxazole remains the DOC for *Pneumocystis jirovecii* pneumonia and *Stenotrophomonas maltophilia*. [3] * **Adverse Effects:** Watch for Megaloblastic anemia (due to folate deficiency) and Stevens-Johnson Syndrome (due to the sulfonamide component). [3]

Question 1

Which of the following antiretroviral drugs is a non-nucleoside reverse transcriptase inhibitor?

Accepted Answer

Efavirenz

Answer

Zidovudine

Answer

Saquinavir

Answer

Stavudine

Question 2

Which of the following can be given as a single dose antimalarial for P.vivax malaria?

Accepted Answer

Pyrimethamine + Sulfadoxime

Answer

Atovaquone + Proguanil

Answer

Artemisinin

Answer

Quinine + Tetracycline

Question 3

Among the drugs listed, which is LEAST likely to be implicated in drug-induced hepatitis?

Accepted Answer

Streptomycin

Answer

Isoniazid

Answer

Rifampicin

Answer

Pyrazinamide

Question 4

Which of the following is NOT included in the treatment of Mycobacterium avium complex?

Accepted Answer

Pyrazinamide

Answer

Ciprofloxacin

Answer

Clarithromycin

Answer

Rifabutin

Question 5

Which of the following antibiotics is not used in the treatment of enterococcal infections?

Accepted Answer

Cephalexin

Answer

Vancomycin

Answer

Linezolid

Answer

Teichoplanin

Question 6

A 29-year-old female diagnosed with AIDS presents with progressive blurring of vision in her right eye. Fundoscopic examination reveals a small, white, opaque lesion on the retina. What is the most appropriate therapy for this patient?

Accepted Answer

Ganciclovir

Answer

Acyclovir

Answer

Amantadine

Answer

Flucytosine

Question 7

Which of the following is NOT a NNRTI?

Accepted Answer

Ritonavir

Answer

Nevirapine

Answer

Efavirenz

Answer

Delavirdine

Question 8

What is the drug of choice for the treatment of chlamydial infection?

Accepted Answer

Doxycycline

Answer

Ampicillin

Answer

Third generation cephalosporins

Answer

Metronidazole

Question 9

Clavulanic acid is given in combination with amoxicillin in order to:

Accepted Answer

Extend amoxicillin's antibacterial spectrum

Answer

Reduce the risk of allergic reactions

Answer

Prolong amoxicillin's half-life

Answer

Reduce the severity of diarrhea

Question 10

In cotrimoxazole, what is the ratio of sulphamethoxazole to trimethoprim?

Accepted Answer

5:1

Answer

2:1

Answer

1:1

Answer

4:5

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?